BR112012006468A2 - métodos de tratamento de inflamação - Google Patents
métodos de tratamento de inflamaçãoInfo
- Publication number
- BR112012006468A2 BR112012006468A2 BR112012006468A BR112012006468A BR112012006468A2 BR 112012006468 A2 BR112012006468 A2 BR 112012006468A2 BR 112012006468 A BR112012006468 A BR 112012006468A BR 112012006468 A BR112012006468 A BR 112012006468A BR 112012006468 A2 BR112012006468 A2 BR 112012006468A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment methods
- inflammation treatment
- methods
- cxcr2
- cxcr4
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 abstract 2
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24521409P | 2009-09-23 | 2009-09-23 | |
US31903910P | 2010-03-30 | 2010-03-30 | |
PCT/US2010/050047 WO2011038149A2 (en) | 2009-09-23 | 2010-09-23 | Methods of treating inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012006468A2 true BR112012006468A2 (pt) | 2016-08-09 |
Family
ID=43796491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012006468A BR112012006468A2 (pt) | 2009-09-23 | 2010-09-23 | métodos de tratamento de inflamação |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2480579A4 (de) |
KR (1) | KR20120105429A (de) |
CN (1) | CN102725311A (de) |
AU (1) | AU2010298249A1 (de) |
BR (1) | BR112012006468A2 (de) |
CA (1) | CA2773978A1 (de) |
IN (1) | IN2012DN02423A (de) |
MX (1) | MX2012003514A (de) |
WO (1) | WO2011038149A2 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
CA2873808C (en) * | 2012-05-17 | 2021-04-27 | Cyon Therapeutics Inc. | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors |
AR098418A1 (es) * | 2013-11-14 | 2016-05-26 | Baxter Healthcare Sa | Factor inhibitorio de imigración de macrófago (mif) como objetivo terapéutico |
EP3426253A4 (de) | 2016-03-11 | 2019-11-06 | Ardea Biosciences, Inc. | Cxcr-2-inhibitoren zur behandlung von kristallarthropathien |
WO2019236528A1 (en) | 2018-06-05 | 2019-12-12 | Anji Pharma (Us) Llc | Compositions and methods for treating pancreatitis |
US20230104343A1 (en) * | 2020-03-11 | 2023-04-06 | Biolinerx Ltd. | Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections |
WO2021219495A1 (en) * | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
CN112656934A (zh) * | 2021-01-22 | 2021-04-16 | 深圳市图微安创科技开发有限公司 | 多肽at03在治疗原发性胆汁性胆管炎药物中的应用 |
EP4378319A1 (de) * | 2022-12-01 | 2024-06-05 | Bioiberica, S.A.U. | Zusammensetzung mit bioaktiven peptiden |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
WO2005065328A2 (en) * | 2003-12-30 | 2005-07-21 | The United States Of America, As Represented By The Department Of Veterans Affairs | Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2009117710A2 (en) * | 2008-03-20 | 2009-09-24 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
-
2010
- 2010-09-23 EP EP10819481.2A patent/EP2480579A4/de not_active Withdrawn
- 2010-09-23 CN CN2010800526286A patent/CN102725311A/zh active Pending
- 2010-09-23 MX MX2012003514A patent/MX2012003514A/es unknown
- 2010-09-23 CA CA2773978A patent/CA2773978A1/en not_active Abandoned
- 2010-09-23 KR KR1020127010455A patent/KR20120105429A/ko not_active Application Discontinuation
- 2010-09-23 IN IN2423DEN2012 patent/IN2012DN02423A/en unknown
- 2010-09-23 AU AU2010298249A patent/AU2010298249A1/en not_active Abandoned
- 2010-09-23 WO PCT/US2010/050047 patent/WO2011038149A2/en active Application Filing
- 2010-09-23 BR BR112012006468A patent/BR112012006468A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2773978A1 (en) | 2011-03-31 |
IN2012DN02423A (de) | 2015-08-21 |
KR20120105429A (ko) | 2012-09-25 |
WO2011038149A3 (en) | 2011-10-27 |
MX2012003514A (es) | 2012-04-19 |
EP2480579A4 (de) | 2013-07-31 |
CN102725311A (zh) | 2012-10-10 |
AU2010298249A1 (en) | 2012-04-19 |
EP2480579A2 (de) | 2012-08-01 |
WO2011038149A2 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012006468A2 (pt) | métodos de tratamento de inflamação | |
NI201200090A (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
WO2009117710A3 (en) | Methods of treating inflammation | |
BRPI0910198A2 (pt) | composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. | |
BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
MX340515B (es) | Terapia antidiabética vasoprotectora y cardioprotectora. | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
EP2493464A4 (de) | Methylsulfonylmethan (msm) zur behandlung wirkstoffresistenter mikroorganismen | |
MX2010006519A (es) | Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina. | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
EP4140487A8 (de) | Kombinationstherapie zur behandlung von krebs | |
BRPI0713447A2 (pt) | composição forma de dosagem oral sólida, e, método para o tratamento de dor | |
AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
CO6531463A2 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
MA32389B1 (fr) | Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
WO2011020061A3 (en) | Compositions and methods of for treating bipolar disorder | |
EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
BRPI1011624A2 (pt) | composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente. | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
BR112013022217A8 (pt) | composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: CAROLUS THERAPEUTICS, INC. (US) , CAROLUS THERAPEU |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |